CRL250516P85000
- 0.20
- -0.31-60.78%
Charles River Newsroom
Wall Street Roars Back From April Tariff Sell-Off: Which Sectors Are Still Underwater?
Earnings Preview: CRL to Report Financial Results Pre-market on May 07
Charles River Associates Backs FY25 Revenue View $715M-$735M, Consensus $718.35M
Press Release: Charles River Associates (CRA) Declares Quarterly Cash Dividend of $0.49 Per Common Share
Press Release: Charles River Associates (CRA) Reports Financial Results for the First Quarter of 2025
Earnings Flash (CRAI) CHARLES RIVER ASSOCIATES Reports Q1 Adjusted EPS $2.22, Vs. FactSet Est of $1.95
Express News | Charles River Associates (CRA) Reports Financial Results for the First Quarter of 2025
Charles River Associates Declares Dividend of 49c >CRAI
Charles River Announces Inaugural Advanced Therapy Incubator Program Cohort
Goldman Sachs: The Q1 performance of U.S. pharmaceutical stocks is reassuring, and the Industry sentiment is slightly becoming more positive.
Goldman Sachs stated that amid cautious sentiment from investors towards the USA pharmaceutical sector before the Earnings Reports season, the performance of USA pharmaceutical companies that have reported results so far for the first quarter has not been worse than expected, and in some cases, it has even exceeded expectations.
Notable Healthcare Headlines for the Week: Merck, Roche and Bausch Health in Focus
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
Vanda Claims FDA 'Unlawfully' Delays Hearing Request on Tradipitant Decision
9 Health Care Stocks With Whale Alerts In Today's Session
Humanized Mouse and Rat Model Market Worth US$409.8 Million in 2030 With 8.2% CAGR | MarketsandMarkets
Upslope Capital Management Sold Charles River (CRL) Due to Thesis Break
Charles River Associates (CRA) Strengthens Its Risk, Investigations & Analytics Practice
Research Alert: CFRA Keeps Hold View On Shares Of Charles River Laboratories International Inc.
Express News | Charles River Laboratories International Inc : Jefferies Cuts Target Price to $100 From $169
Notable Healthcare Headlines for the Week: UnitedHealth, Eli Lilly, J&J in Focus